Chronic kidney disease after liver, cardiac, lung, heart-lung, and hematopoietic stem cell transplant.
Patient survival after cardiac, liver, and hematopoietic stem cell transplant (HSCT) is improving; however, this survival is limited by substantial pretransplant and treatment-related toxicities. A major cause of morbidity and mortality after transplant is chronic kidney disease (CKD). Although the majority of CKD after transplant is attributed to the use of calcineurin inhibitors, various other conditions such as thrombotic microangiopathy, nephrotic syndrome, and focal segmental glomerulosclerosis have been described. Though the immunosuppression used for each of the transplant types, cardiac, liver and HSCT is similar, the risk factors for developing CKD and the CKD severity described in patients after transplant vary. As the indications for transplant and the long-term survival improves for these children, so will the burden of CKD. Nephrologists should be involved early in the pretransplant workup of these patients. Transplant physicians and nephrologists will need to work together to identify those patients at risk of developing CKD early to prevent its development and progression to end-stage renal disease.
Hingorani
Sangeeta
S
Pediatrics-University of Washington, 4800 Sandpoint Way NE M1-5, Seattle, WA 98015, USA. sangeeta.hingorani@seattlechildrens.org
D000293:Adolescent; D002648:Child; D002675:Child, Preschool; D002908:Chronic Disease; D016027:Heart Transplantation / Q000009:adverse effects*; D016041:Heart-Lung Transplantation / Q000009:adverse effects*; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects*; D006801:Humans; D007674:Kidney Diseases / Q000209:etiology* / Q000401:mortality / Q000628:therapy; D016031:Liver Transplantation / Q000009:adverse effects*; D016040:Lung Transplantation / Q000009:adverse effects*; D018570:Risk Assessment; D012307:Risk Factors; D016896:Treatment Outcome